The European Young Investigators is an exciting educational project that aims to foster deeper and more frequent exchanges among young HIV experts across Europe. The fourth EACS European Young Investigators took place on 1-2 July 2022 in Brussels, Belgium at the Royal Academies for Science and the Arts.
This two-day event which involves plenary sessions and workshops is organised by a scientific committee composed of young experts. A young expert is a clinician or investigator who has published three or four articles, spoken at a major conference and who has between five to eight years of activity in the HIV field.
YING 2022 plenaries and workshops
Plenaries
Knowledge gaps in SARS CoV-2 and HIV
Tops and flops in the field
Equality, Diversity, and Inclusion in trials and why it matters
Vaccination and cure
Workshops
Examples of successful 90-90-90
Translation of research into clinical practice
Complex clinical cases
Public and Patient Involvement
Organising Committee
Annemarie Wensing (Chair)
University Medical Center Utrecht
Utrecht, Netherlands
Tristan Barber (Vice-Chair)
Royal Free London NHS Foundation Trust
London, United Kingdom
Laura Waters
Mortimer Market Centre, Central and North West London NHS Foundation Trust
London, United Kingdom
Jose Bernardino
Hospital Universitario La Paz
Madrid. Spain
Faculty
Programme
Report
Travel and Accommodation
Synopses
The YING conference 2022, 1-2 July 2022, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 8 European CME Credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.
20th European AIDS Conference
15-18 October 2025 Paris, France
EACS Guidelines updated
The EACS 12.1 and the app are available for free on
Educational Programme
Training and educating the next generation of clinicians and researchers is an EACS core activity.
EACS Resource Library
Access all scientific content of EACS core activities! (members only)
New Interim Guidance
Interim Guidance on the Use of Statin Therapy for the Primary Prevention of Cardiovascular Disease in People with HIV